ETF Holdings Breakdown of ACRS
| Stock Name | Aclaris Therapeutics Inc |
| Ticker | ACRS(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US00461U1051 |
| LEI | 5493000B2LQ9QTW1DF52 |
ACRS institutional holdings
The adjusted close for ACRS on 2025-12-24 was 3.04
The following institutional investment holdings of ACRS have been identified
Book value of shares is calculated on the adjusted close price of each day (row).News associated with ACRS
- Reviewing Aclaris Therapeutics (NASDAQ:ACRS) and GelStat (OTCMKTS:GSAC)
- Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) and GelStat (OTCMKTS:GSAC – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings. Analyst Recommendations This is a summary of current […] - 2025-09-04 02:46:48
- Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) PT at $8.71
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has been given an average recommendation of “Buy” by the nine analysts that are presently covering the firm, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month […] - 2025-08-04 02:26:49
- Alps Advisors Inc. Buys 21,022 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
- Alps Advisors Inc. increased its position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) by 36.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 78,782 shares of the biotechnology company’s stock after buying an additional 21,022 shares during the […] - 2025-07-18 04:50:52
- Head-To-Head Survey: Aclaris Therapeutics (NASDAQ:ACRS) vs. Plus Therapeutics (NASDAQ:PSTV)
- Plus Therapeutics (NASDAQ:PSTV – Get Free Report) and Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends. Institutional & Insider Ownership 3.3% of Plus […] - 2025-07-10 03:07:05
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Recommendation of “Buy” from Brokerages
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has been given a consensus recommendation of “Buy” by the nine research firms that are presently covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 […] - 2025-07-07 03:17:01
- Wedbush Reaffirms “Outperform” Rating for Aclaris Therapeutics (NASDAQ:ACRS)
- Wedbush reissued their outperform rating on shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) in a report released on Monday morning,RTT News reports. The brokerage currently has a $8.00 price objective on the biotechnology company’s stock. Other equities research analysts have also issued reports about the company. HC Wainwright reaffirmed a “buy” rating and issued […] - 2025-06-24 03:12:46
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of “Buy” by Brokerages
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has earned a consensus recommendation of “Buy” from the nine research firms that are covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among […] - 2025-06-12 04:56:58
- Squarepoint Ops LLC Has $726,000 Stock Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
- Squarepoint Ops LLC boosted its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) by 108.3% during the fourth quarter, Holdings Channel reports. The fund owned 292,892 shares of the biotechnology company’s stock after acquiring an additional 152,312 shares during the period. Squarepoint Ops LLC’s holdings in Aclaris Therapeutics were worth $726,000 at […] - 2025-06-03 05:05:01
- Jefferies Financial Group Inc. Increases Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
- Jefferies Financial Group Inc. increased its position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) by 253.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 40,700 shares of the biotechnology company’s stock after acquiring an additional 29,200 shares during the quarter. Jefferies Financial Group […] - 2025-06-02 05:40:59
- Wedbush Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS)
- Equities researchers at Wedbush assumed coverage on shares of Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) in a report released on Wednesday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $8.00 price target on the biotechnology company’s stock. Wedbush’s price target points to a potential upside of 447.95% from the company’s current […] - 2025-05-30 02:16:45
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stake Lowered by Two Sigma Advisers LP
- Two Sigma Advisers LP reduced its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) by 24.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 977,400 shares of the biotechnology company’s stock after selling 324,100 shares during the […] - 2025-05-29 06:22:53
- Man Group plc Makes New Investment in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
- Man Group plc acquired a new position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) during the 4th quarter, Holdings Channel.com reports. The fund acquired 53,534 shares of the biotechnology company’s stock, valued at approximately $133,000. Other large investors have also recently added to or reduced their stakes in the company. ExodusPoint Capital […] - 2025-05-29 05:40:58
- Millennium Management LLC Sells 1,046,551 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
- Millennium Management LLC reduced its position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) by 34.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,959,047 shares of the biotechnology company’s stock after selling 1,046,551 shares during the quarter. Millennium Management LLC’s holdings in Aclaris Therapeutics […] - 2025-05-29 04:52:50
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $10.00 Consensus Target Price from Analysts
- Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) have been given an average recommendation of “Buy” by the eight analysts that are currently covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 […] - 2025-05-23 04:30:49
- Graham Capital Management L.P. Takes $35,000 Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
- Graham Capital Management L.P. bought a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) during the fourth quarter, Holdings Channel reports. The institutional investor bought 14,172 shares of the biotechnology company’s stock, valued at approximately $35,000. A number of other large investors also recently modified their holdings of ACRS. ExodusPoint Capital Management LP […] - 2025-05-20 05:09:15
- Schonfeld Strategic Advisors LLC Invests $327,000 in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
- Schonfeld Strategic Advisors LLC acquired a new stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 131,895 shares of the biotechnology company’s stock, valued at approximately $327,000. A number of other hedge […] - 2025-05-13 05:31:18
- Aclaris Therapeutics (NASDAQ:ACRS) Price Target Lowered to $9.00 at Scotiabank
- Aclaris Therapeutics (NASDAQ:ACRS – Free Report) had its price target reduced by Scotiabank from $15.00 to $9.00 in a report released on Friday morning,Benzinga reports. They currently have a sector outperform rating on the biotechnology company’s stock. Several other research analysts have also recently commented on the stock. Cantor Fitzgerald initiated coverage on shares of […] - 2025-05-12 02:58:53
- Geode Capital Management LLC Cuts Stock Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
- Geode Capital Management LLC decreased its holdings in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) by 6.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 789,597 shares of the biotechnology company’s stock after selling 56,849 shares during the period. Geode […] - 2025-04-30 04:36:52
- Aclaris Therapeutics Appoints Jesse Hall As CMO
- (RTTNews) - Aclaris Therapeutics, Inc. (ACRS), a clinical-stage biopharmaceutical company, on Tuesday announced the appointment of Jesse Hall as Chief Medical Officer. The transition is effective May 1. - 2025-04-29 08:47:49
- ExodusPoint Capital Management LP Invests $26,000 in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
- ExodusPoint Capital Management LP purchased a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 10,637 shares of the biotechnology company’s stock, valued at approximately $26,000. A number of other […] - 2025-04-15 04:38:56
- Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Increases By 26.7%
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 6,030,000 shares, an increase of 26.7% from the February 28th total of 4,760,000 shares. Currently, 9.0% of the company’s stock are sold short. Based on an average trading volume […] - 2025-04-03 02:25:04
- Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target at $11.00
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has received an average recommendation of “Buy” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year price target […] - 2025-03-07 04:44:45
- Aclaris Therapeutics (NASDAQ:ACRS) Upgraded to “Strong-Buy” at Cantor Fitzgerald
- Cantor Fitzgerald upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) to a strong-buy rating in a research report sent to investors on Tuesday,Zacks.com reports. Cantor Fitzgerald also issued estimates for Aclaris Therapeutics’ FY2025 earnings at ($0.54) EPS. Several other equities research analysts also recently issued reports on ACRS. HC Wainwright raised Aclaris Therapeutics from […] - 2025-03-07 04:10:47
- Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Target Price at $11.00
- Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has been assigned an average recommendation of “Buy” from the seven research firms that are covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year target […] - 2025-02-14 06:22:49
- Aclaris Therapeutics (NASDAQ:ACRS) Downgraded by StockNews.com to “Sell”
- StockNews.com cut shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) from a hold rating to a sell rating in a report published on Saturday. Several other equities research analysts have also commented on the stock. BTIG Research raised shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price […] - 2025-02-11 04:13:09
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.
Copyright Market Footprint Ltd. Privacy Policy
4.6%